Imaging in the Era of COVID-19 Presentation
Transcript of Imaging in the Era of COVID-19 Presentation
Perspectum Ltd.
Dr. Rajarshi Banerjee
Imaging in the Era of COVID-19: Maintaining Safety Above All
Perspectum Ltd.
Your speaker: Dr. Rajarshi Banerjee
Dr. Rajarshi Banerjee is the CEO of Perspectum, he graduated in medicine from the University of Oxford and went on to complete a Masters in Public Health at the London School of Hygiene and Tropical Medicine, before returning to Oxford, for his doctorate.
He developed multiparametric liver MRI techniques at the University of Oxford, which led to the creation of Perspectum. He is an expert on liver imaging and a consultant physician for Oxford University Hospitals NHS Foundation Trust.
Rajarshi has many years of experience in running clinical trials and working in multidisciplinary scientific teams to develop applications for cutting-edge imaging technology, and is a keen advocate of adaptive trial design.
Perspectum Ltd.
Key topics to cover
Attendees are encouraged to ask questions throughout the webinar!
How the global
pandemic is impacting medical
research.
Prioritising safety for
outpatient imaging.
The impact of COVID-19 on societal well-
being and healthcare.
The growing importance of
imaging biomarkers.
Perspectum Ltd.
How the global pandemic is impacting medical researchSponsors who are actively running trials
March
April May/June
Minimize the impact on quality
data collected
Non-covid clinical research has been suspended in most academic settings
Most large pharma companies have
suspended recruitment for
non-covid research
This coincides with lockdown in most geographies
Lock down restrictions are likely
to ease in Europe
When will trials resume?
Perspectum Ltd.
How the global pandemic is impacting medical researchSponsors who are starting up studies
• Find ways to work quickly. Patients need treatments.
• Expect increased enrolment competition when trials resume.
• "Hey, we do what we do best. We improvise, all right?" - Brian O'Connor | Fast and Furious 6 (2013)
Perspectum Ltd.
Setting up a study quickly & safely.A case study from COVERSCAN
Perspectum Ltd.
Study set up 30 days from initiation to first patient in
Start of study protocol drafting
Submitted to the REC
REC Meeting
REC Initial Feedback
Response to REC
REC Approval
First Study Day
Perspectum Ltd.
First Study Day28 April 2020
AM
AM
AM
AM
05:00
08:30
10:30
11:00
Arrival of Alliance Medical truck(s)
Study Team on site at Gemini
ITV Meridian
First Participant
Perspectum Ltd.
Study Visit FlowMaintaining safety above all
Step 1
Step 2
Perspectum Ltd.
The Alliance Medical “Kit”Maintaining safety above all
Mobile Clinical Suite and CT Scanner
Mobile MRI Scanner
Perspectum Ltd.
Mobile Clinical Suite & CT Scanner
Video cred Vadim Belenov
Perspectum Ltd.
Mobile MRI Scanner
Perspectum Ltd.
40 minutes scan
Perspectum Ltd.
Prioritising safety for outpatient imaging
Perspectum Ltd.
Prioritising safety for outpatient imagingPPE: The MaskFFP3 (European standard) respirators filter 99% of particles.
FFP2 respirators are specified to filter 94% of particles
The N99 (American standard) respirator is an alternative to the FFP3 and filters
99% of particles
An N95 respirator is specified to filter 95% of particles and is a close equivalent to the FFP2
Other equivalents:• KN95 (China)• P2 (Australia/New Zealand)• DF FFR (Japan)
The Type IIR (European Standard) fluid resistant surgical mask is the “regular” surgical mask often used in clinical settings
The Level 2 (American standard) fluid resistant surgical mask is equivalent to the Type IIR
Perspectum Ltd.
Participant Operator
Prioritising safety for outpatient imagingPPE: The Mask
Type IIR/Level 2 Fluid Resistant Mask
Respirator(N95 non-valved&FFP3 valved)
Perspectum Ltd.
Prioritising safety for outpatient imagingUltrasound / echocardiography
• Ultrasound transducers and cables should be cleaned and disinfected between patients. • Use only single-use gel packets.
• Technicians should wear full PPE.• Clinicians who are at increased health
risk should not perform ultrasound procedures • Comordities: Over 60, obesity, hypertension,
and diabetes (Richardson et. al., 2020)• Cardiovasuclar disease and respiratory
system disease (Yang J et. Al., 2020)
Perspectum Ltd.
Prioritising safety for outpatient imagingUltrasound / echocardiography
Perspectum Ltd.
Prioritising safety for outpatient imagingMRI/CT guidelines
2 3 4 5
Virtual patient check-in
Patient in waiting room
MRI/CT Scan
Deep clean the suite
15 minutesBetween patients
• Social Distancing• Low Patient Volume• Masks Provided• Replace fabric chairs
• Patient and technologist in separate rooms
• Remote activations available
• Sanitize the scanner
• Clean coils & table
Perspectum Ltd.
Fatty Liver Disease is fundamental to COVID-19The underdiagnosed, asymptomatic health condition
• NAFLD is recognized as the most prevalent chronic liver disease globally, with a well documented association with obesity and metabolic syndrome.• Obesity is the biggest single chronic risk
factor for hospital admission for COVID-19 in patients under 60, increasing the risk 2-3-fold.
• Identifying high-risk patients and assessing multi-organ involvement is vital.• NASH awareness may increase as a result
"Understanding the impact of COVID-19 on specific patient populations such as those with obesity, diabetes, fatty liver disease and NASH is essential to providing actionable advice to clinicians and patients to provide optimal care and avoid needless deaths.”
- Donna Cryer, President of the Global Liver Institute
Perspectum Ltd.
The impact of COVID-19 on societal well-being and healthcare
• Best time to invest in healthcare tech is now! • Second chance at missed opportunities.
• Eli Lilly’s CEO David Ricks said the biopharma industry has a “once in a generation opportunity to reset" its reputation.
• Gilead CEO Daniel O’Day believes the pandemic will help for “innovative, research-based companies,” • The public will recognize the industry’s “ability to solve a human
crisis like this, because of the decades of investment,” he said. “The tone is different in Washington."
Perspectum Ltd.
How will COVID-19 affect future endpoints? The growing importance of imaging biomarkers
COVID-19 has highlighted the importance of non-contact, non-invasive
testing
Prior authorization for
NASH will be imaging and
bloods
Biopsy is inherently
more invasive
Now more than ever, it’s important to have
a way to diagnose NAFLD/NASH patients due to the underlying
comorbidities associated with
COVID-19.
Perspectum Ltd.
Questions & Answers
Perspectum Ltd.
Thank youTo find out more visit:
Perspectum.comTo find out more information:
Thank you
Perspectum.com
@PerspectumGroup
@perspectum.diagnostics